IL316772A - Dose transmitters containing complement factor I for the treatment of eye diseases - Google Patents
Dose transmitters containing complement factor I for the treatment of eye diseasesInfo
- Publication number
- IL316772A IL316772A IL316772A IL31677224A IL316772A IL 316772 A IL316772 A IL 316772A IL 316772 A IL316772 A IL 316772A IL 31677224 A IL31677224 A IL 31677224A IL 316772 A IL316772 A IL 316772A
- Authority
- IL
- Israel
- Prior art keywords
- cfi
- per eye
- weeks
- seq
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338392P | 2022-05-04 | 2022-05-04 | |
| PCT/US2023/066620 WO2023215840A1 (en) | 2022-05-04 | 2023-05-04 | Complement factor i dosing regimens for treating ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316772A true IL316772A (en) | 2025-01-01 |
Family
ID=86760162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316772A IL316772A (en) | 2022-05-04 | 2023-05-04 | Dose transmitters containing complement factor I for the treatment of eye diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250177482A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4518881A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515091A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250008764A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119698286A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023265150A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251504A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316772A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400627A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215840A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3117551A1 (en) * | 2018-10-23 | 2020-04-30 | Gemini Therapeutics Inc. | Compositions and methods for treating age-related macular degeneration and other diseases |
| GB201821082D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
| WO2021257480A2 (en) * | 2020-06-14 | 2021-12-23 | Catalyst Biosciences, Inc. | Complement factor i-related compositions and methods |
-
2023
- 2023-05-04 EP EP23730321.9A patent/EP4518881A1/en active Pending
- 2023-05-04 AU AU2023265150A patent/AU2023265150A1/en active Pending
- 2023-05-04 JP JP2024564919A patent/JP2025515091A/ja active Pending
- 2023-05-04 CA CA3251504A patent/CA3251504A1/en active Pending
- 2023-05-04 IL IL316772A patent/IL316772A/en unknown
- 2023-05-04 KR KR1020247040205A patent/KR20250008764A/ko active Pending
- 2023-05-04 CN CN202380045885.4A patent/CN119698286A/zh active Pending
- 2023-05-04 TW TW112116648A patent/TW202400627A/zh unknown
- 2023-05-04 WO PCT/US2023/066620 patent/WO2023215840A1/en not_active Ceased
-
2024
- 2024-11-01 US US18/935,289 patent/US20250177482A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250008764A (ko) | 2025-01-15 |
| JP2025515091A (ja) | 2025-05-13 |
| AU2023265150A1 (en) | 2024-11-14 |
| CA3251504A1 (en) | 2023-11-09 |
| CN119698286A (zh) | 2025-03-25 |
| WO2023215840A1 (en) | 2023-11-09 |
| EP4518881A1 (en) | 2025-03-12 |
| US20250177482A1 (en) | 2025-06-05 |
| TW202400627A (zh) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299048A (en) | Variants of complement factor - 1 fusion structures and preparations containing them and their uses | |
| IL287019B1 (en) | Compositions and methods for internalizing enzymes | |
| IL262060B (en) | A method for selecting recombinant proteins with a high amount of mannose-6-phosphate | |
| IL322464A (en) | Methods and compositions for administering therapeutic protein | |
| IL271193B2 (en) | Preparations and methods for internalizing enzymes | |
| IL302720A (en) | GDF15 fusion proteins and their uses | |
| US20140186326A1 (en) | Modified acid alpha glucosidase with accelerated processing | |
| IL282987B2 (en) | Delivery constructs for transcytosis and related methods | |
| EP4031117B1 (en) | Ngf mutant for use in treatment or prevention of ophthalmic disorders | |
| IL270503B2 (en) | Depletion of homocysteine by human enzymes for the treatment of patients with hyperhomocysteinemia and homocystinuria | |
| KR20240000391A (ko) | N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도 | |
| IL262044A (en) | Conjugated c1 esterase inhibitor and uses thereof | |
| US20250011379A1 (en) | Complement factor i-related compositions and methods | |
| IL268971B2 (en) | Polypeptide, polypeptide fragment, derivative thereof, and applications thereof | |
| CN108291246A (zh) | 修饰的溶酶体蛋白及其产生 | |
| US20250177482A1 (en) | Complement factor i dosing regimens for treating ocular diseases | |
| EP4260871A1 (en) | Optical nerve protecting agent containing anti-lrp1 antibody | |
| IL305246A (en) | Mutated arylsulfatase a with increased stability | |
| WO2025053776A1 (ru) | Антитела против рецептора трансферрина и их применение | |
| IL313777A (en) | Complement factor-i formulations | |
| Cendales | Structure and function studies of recombinant clusterin |